Sector consensus Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.04 USD | -0.89% |
|
-7.40% | +11.12% |
| 07-20 | Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026 | RE |
| 07-07 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 59.31 | +19.87% | 16 | ||||||
| 150.47 | +18.07% | 18 | ||||||
| 1,006.33 | +11.05% | 15 | ||||||
| 106.86 | +31.98% | 20 | ||||||
| 196.18 | +82.65% | 22 | ||||||
| 40.66 | +19.98% | 23 | ||||||
| 2,392.08 | +25.63% | 15 | ||||||
| 563.1 | +7.98% | 17 | ||||||
| 1,073.31 | -6.67% | 7 | ||||||
| 52.07 | -6.44% | 15 | ||||||
| 102.91 | +18.59% | 11 | ||||||
| 679.64 | +25.08% | 14 | ||||||
| 147.68 | +66.28% | 20 | ||||||
| 21.5 | +92.04% | 13 | ||||||
| 107.8 | +31.59% | 20 | ||||||
| 99.9 | +32.5% | 15 | ||||||
| 82.5 | -1.37% | 10 | ||||||
| 103.93 | +3.94% | 15 | ||||||
| - | - | - | - | |||||
| 109 | +95.9% | 9 | ||||||
| Average | 373.43 | +29.93% | 16 | ||||||
| Weighted average by Cap. | 462.08 | +26.53% | 16 |
- Stock Market
- Stocks
- SRRK Stock
- Sector Scholar Rock Holding Corporation
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
